Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Loncastuximab tesirine - ADC Therapeutics

Drug Profile

Loncastuximab tesirine - ADC Therapeutics

Alternative Names: ADCT-402; Anti-CD19-PBD-conjugate-ADC; Lonca; Lonca-T; loncastuximab tesirine-lpyl; MT-2111; ZYNLONTA

Latest Information Update: 10 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ADC Therapeutics; Spirogen
  • Developer ADC Therapeutics; Mitsubishi Tanabe Pharma Corporation; Swedish Orphan Biovitrum
  • Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunotoxins; Monoclonal antibodies; Pyrroles
  • Mechanism of Action Alkylating agents; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diffuse large B cell lymphoma
  • Preregistration B-cell lymphoma
  • Phase II Follicular lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Mantle-cell lymphoma
  • Phase I Non-Hodgkin's lymphoma
  • Discontinued Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 06 May 2024 Efficacy and adverse events data from the phase I clinical trial in Non-Hodgkin's lymphoma released by ADC Therapeutics
  • 06 May 2024 Efficacy and adverse events data from a phase II trial in Marginal zone B-cell lymphoma released by ADC Therapeutics
  • 09 Apr 2024 Swedish Orphan Biovitrum announces intention to launch loncastuximab tesirine in Europe and other countries in 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top